Ozbey, DogukanSaribas, SuatKocazeybek, Bekir2025-02-172025-02-17202501007-93272219-284010.3748/wjg.v31.i6.1012662-s2.0-85214579478https://doi.org/10.3748/wjg.v31.i6.101266https://hdl.handle.net/20.500.14517/7659Inflammatory bowel diseases (IBDs) are classified into two distinct types based on the area and severity of inflammation: Crohn's disease (CD) and ulcerative colitis. In CD, gut bacteria can infiltrate mesenteric fat, causing expansion known as creeping fat, which may limit bacterial spread and inflammation but can promote fibrosis. The gut bacteria composition varies depending on whether the colon or ileum is affected. Fecal microbiota transplantation (FMT) transfers feces from a healthy donor to restore gut microbiota balance, often used in IBD patients to reduce inflammation and promote mucosal repair. The use of FMT for CD remains uncertain, with insufficient evidence to fully endorse it as a definitive treatment. While some studies suggest it may improve symptoms, questions about the duration of these improvements and the need for repeated treatments persist. There is a pressing need for methods that provide long-term benefits, as highlighted by Wu et al's research.eninfo:eu-repo/semantics/closedAccessCrohn'S DiseaseFecal Microbiota TransplantationGut MicrobiotaInflammatory Bowel DiseaseMesenteric Adipose TissueLetterQ2Q1316WOS:001413497100006